Abbisko Therapeutics discovers and develops small‑molecule precision‑oncology and immuno‑oncology drugs that target validated oncogenic drivers and immune pathways, such as CSF‑1R, FGFR4, KRAS G12D, EGFR C797S, PD‑L1 and CXCR4. Leveraging an in‑house multi‑dimensional R&D platform that integrates cancer genomics, medicinal chemistry and biomarker science, the company advances a pipeline of over ten oral candidates, with several in clinical stages, through monotherapy and combination trials for solid tumors and rare diseases in China and globally.

Structure Therapeutics develops orally available small molecule drugs targeting G protein-coupled receptors (GPCRs) to provide biologic-like activity for chronic diseases such as type 2 diabetes, obesity, and pulmonary conditions. By utilizing advanced computational chemistry and structure-based technologies, the company aims to overcome the limitations of current biologic and peptide therapies.